| J9271 | Injection, pembrolizumab, 1 mg | 32,800 | $40 | $1.3M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 24,660 | $40 | $912.4K |
| J0897 | Injection, denosumab, 1 mg | 17,460 | $20 | $314.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,270 | $110 | $134.7K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 750 | $150 | $112.6K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 670 | $120 | $82.9K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 10,380 | $10 | $62.3K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 500 | $90 | $44.9K |
| 99205 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider… | 200 | $190 | $36.5K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 230 | $100 | $23.3K |